These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 29326437)

  • 1. Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance.
    Ikink GJ; Boer M; Bakker ERM; Vendel-Zwaagstra A; Klijn C; Ten Hoeve J; Jonkers J; Wessels LF; Hilkens J
    Oncogene; 2018 Mar; 37(12):1594-1609. PubMed ID: 29326437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
    Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
    PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation.
    Ikink GJ; Boer M; Bakker ER; Hilkens J
    Nat Commun; 2016 Nov; 7():13567. PubMed ID: 27876799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
    Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
    J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas.
    Theodorou V; Boer M; Weigelt B; Jonkers J; van der Valk M; Hilkens J
    Oncogene; 2004 Aug; 23(36):6047-55. PubMed ID: 15208658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genes affected by mouse mammary tumor virus (MMTV) proviral insertions in mouse mammary tumors are deregulated or mutated in primary human mammary tumors.
    Callahan R; Mudunur U; Bargo S; Raafat A; McCurdy D; Boulanger C; Lowther W; Stephens R; Luke BT; Stewart C; Wu X; Munroe D; Smith GH
    Oncotarget; 2012 Nov; 3(11):1320-34. PubMed ID: 23131872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity.
    Maric G; Annis MG; MacDonald PA; Russo C; Perkins D; Siwak DR; Mills GB; Siegel PM
    Oncogene; 2019 Jun; 38(26):5294-5307. PubMed ID: 30914799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β2-AR signaling controls trastuzumab resistance-dependent pathway.
    Liu D; Yang Z; Wang T; Yang Z; Chen H; Hu Y; Hu C; Guo L; Deng Q; Liu Y; Yu M; Shi M; Du N; Guo N
    Oncogene; 2016 Jan; 35(1):47-58. PubMed ID: 25798840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice.
    Ma Z; Parris AB; Xiao Z; Howard EW; Kosanke SD; Feng X; Yang X
    J Exp Clin Cancer Res; 2017 Jan; 36(1):6. PubMed ID: 28061785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer.
    Theodorou V; Kimm MA; Boer M; Wessels L; Theelen W; Jonkers J; Hilkens J
    Nat Genet; 2007 Jun; 39(6):759-69. PubMed ID: 17468756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activating HER2 mutations in HER2 gene amplification negative breast cancer.
    Bose R; Kavuri SM; Searleman AC; Shen W; Shen D; Koboldt DC; Monsey J; Goel N; Aronson AB; Li S; Ma CX; Ding L; Mardis ER; Ellis MJ
    Cancer Discov; 2013 Feb; 3(2):224-37. PubMed ID: 23220880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
    Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
    Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis.
    Patel Y; Soni M; Awgulewitsch A; Kern MJ; Liu S; Shah N; Singh UP; Chen H
    Oncogene; 2019 Jan; 38(3):445-453. PubMed ID: 30104710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.
    Landis MD; Seachrist DD; Abdul-Karim FW; Keri RA
    Oncogene; 2006 Jun; 25(23):3325-34. PubMed ID: 16434967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
    Liu B; Ordonez-Ercan D; Fan Z; Edgerton SM; Yang X; Thor AD
    Int J Cancer; 2007 May; 120(9):1874-82. PubMed ID: 17266042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.
    Kirouac DC; Du J; Lahdenranta J; Onsum MD; Nielsen UB; Schoeberl B; McDonagh CF
    PLoS Comput Biol; 2016 Apr; 12(4):e1004827. PubMed ID: 27035903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
    Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
    Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.